Lung microbiota and bacterial abundance in bronchiectasis

Respiratory Research Review
Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis Authors: Serisier DJ et al.
Summary:
The BLESS trial randomised adult nonsmokers with non-CF bronchiectasis with a history of ≥2 infective exacerbations in the prior year to receive erythromycin 400mg (n=59) or placebo (n=58); the study completion rate was 91.5%. Compared with placebo, erythromycin was associated with: i) significant reductions in mean protocol-defined pulmonary exacerbations both overall and in those with Pseudomonas aeruginosa airway infection at baseline (1.29 and 1.32, respectively, vs. 1.97 per patient per year; p values 0.003 and 0.02); ii) median 24-hour sputum production (median difference 4.3g; p=0.01); iii) attenuation of change in postbronchodilator FEV 1 (difference 2.2 percent predicted; p=0.04); and iv) a greater increase in the proportion of macrolide-resistant oropharyngeal streptococci (27.7% vs. 0.04%; p<0.001).
Comment: This is one of three studies investigating the role of long-term antibiotics in bronchiectasis. The authors noted the limited efficacy of inhaled steroids, mucolytics and prolonged oral antibiotics. They chose erythromycin because it is cheaper than other macrolides and induces less resistance. Low-dose erythromycin reduced exacerbations of bronchiectasis, particularly in patients infected with pseudomonal infection. It didn't reduce cough, C-reactive protein level or quality of life. It did increase macrolide-resistant oropharyngeal organisms. Bottom line: long-term low-dose erythromycin reduced exacerbations, protected against lung decline and increased bacterial resistance -its place in treatment is currently unclear.
Reference : JAMA 2013; 309(12):1260-7 Abstract Effect of azithromycin maintenance treatment on infectious exacerbations among patients with noncystic fibrosis bronchiectasis Authors: Altenburg J et al.
The BAT (Bronchiectasis and long-term Azithromycin Treatment) RCT was conducted in 14 hospitals in the Netherlands among 83 outpatients with non-CF bronchiectasis and ≥3 lower respiratory tract infections in the preceding year. Patients received either azithromycin 250 mg/day (n=43) or placebo (n=40) for 12 months. At 1 year, the median number of exacerbations was significantly lower with azithromycin than placebo (0 vs. 2; p<0.001). Thirty-two (80%) placebo-treated versus 20 (46%) azithromycin-treated individuals had ≥1 exacerbation (hazard ratio 0.29 [95% CI 0.16, 0.51]). In a mixed-model analysis, change in FEV 1 (% of predicted) over time differed between groups, with an increase of 1.03% per 3 months in the azithromycin group and a decrease of 0.10% per 3 months in the placebo group (p=0.047). Gastrointestinal adverse events were reported more often by azithromycin-than placebo-treated patients (40% vs. 5%; relative risk 7.44 [95% CI 0.97, 56.88] for abdominal pain and 8.36 [1.10, 63 .15] for diarrhoea), but none had to subsequently discontinue study treatment. Notably, a macrolide resistance rate of 88% was noted in azithromycin-treated individuals, compared with 26% in the placebo group.
Comment: These Dutch authors performed a study similar to the NZ Embrace study (Respiratory Research Review Issue 82); however, they offered Azithromycin 250mg once daily for 12 months, versus 500mg three times a week for 6 months. Like BLESS and EMBRACE, they also reduced exacerbations and time to first exacerbation. They demonstrated a modest improvement in FEV 1 and spirometry; but also gastrointestinal side effects (40%) and increased macrolide resistant organism (88%). Stuart Elborn and Micheal Tunney carefully consider these issues in their accompanying editorial (JAMA 2013; 309[12] :1295-6). Bottom line: a role of long term macrolides in bronchiectasis is emerging; however, antibiotic resistance is a concern.
Reference: JAMA 2013; 309(12) Summary: These researchers measured bacterial abundance and community composition in 40 sputum samples from patients with clinically stable bronchiectasis before and after antibiotic therapy for exacerbations. Aerobic bacteria were present in all samples, while anaerobic bacteria were present in 83%. Pseudomonas aeruginosa (n=10), Haemophilus influenzae (n=12), Prevotella (n=18) and Veillonella (n=13) were the most dominant organisms. Pyrosequencing revealed 113 distinct microbial taxa in >150,000 sequences. No change was seen in total, aerobic or anaerobic micro-organism load post-treatment, and only a limited shift in community composition was seen. There was good agreement between culture and pyrosequencing for aerobic bacteria, but agreement for other genera, including anaerobes, was worse, due mainly to detection with pyrosequencing but not culturing.
Comment: This carefully designed study challenges our thinking of bronchiectasis. Patients with bronchiectasis develop exacerbations with fever, sputum and dyspnoea. Are these exacerbations caused by a new bacterial strain or species, a change in the bacterial community or a spread of infection to new regions of the lung? The authors investigated 40 patients with bronchiectasis during stable phases, exacerbation and post-treatment. They found a large number of organisms, including Streptococcus, Pseudomonas and Haemophilus spp. However, the bottom line: the microbiota in the lung remained stable through baseline, exacerbation and treatment making it unlikely that changed microbiota composition accounts for exacerbations. Summary: Indigenous Australian, Māori and Pacific Island children aged 1-8 years with bronchiectasis or chronic suppurative lung disease, stratified by study site and exacerbation frequency, received azithromycin 30 mg/kg (n=45) or placebo (n=44) each week for 12-24 months (mean 20.7) in this RCT; the trial was terminated early for feasibility reasons. Compared with placebo, azithromycin was associated with a significantly lower exacerbation rate (incidence rate ratio 0.50 [95% CI 0.35, 0.71; p<0.0001]), but significantly higher carriage of azithromycin-resistant bacteria (46% vs. 11%; p=0.002). Azithromycin and placebo were respectively associated with 112 and 209 adverse events, with 71 and 132 nonpulmonary infections and 22 and 48 bronchiectasis-related events; no serious adverse events were attributed to the intervention.
Comment: Indigenous children in high-income countries have a heavy burden of bronchiectasis unrelated to CF. This combined Australian and NZ study enrolled indigenous Australian, Māori and Pacific Island children aged 1-8 years into a trial receiving once weekly azithromycin or placebo for up to 24 months. As in the adult studies, azithromycin halved the number of exacerbations at the cost of increasing carriage of azithromycin-resistant bacteria. Bottom line: as clinicians we need to weigh up if the preservation of lung function and improvement of quality of life justifies the emergence of long-term resistant bacteria.
Reference: Lancet Respir Med 2013;1(8):610-20 Abstract
Ciprofloxacin dry powder for inhalation in non-cystic fibrosis bronchiectasis Authors: Wilson R et al.
Summary:
This phase II trial randomised adults with predefined potential respiratory pathogens (including Pseudomonas aeruginosa and Haemophilus influenzae) to receive dry powder inhaled ciprofloxacin 32.5mg (n=60) or placebo (n=64) twice daily for 28 days; follow-up was 56 days. Compared with placebo, dry powder ciprofloxacin was associated with a significant reduction in total sputum bacterial load at the end of treatment (-3.62 vs. -0.27 log 10 CFU/g; p<0.001), after which counts increased, and a significantly greater pathogen eradication rate at the end of treatment (35% vs. 8%; p=0.001). Safety data showed no abnormal findings, with low rates of bronchospasm.
Comment: This study explored the role of inhaled dry powder ciprofloxacin 32.5mg twice daily during a stable phase for 28 days. Participants with idiopathic or postinfective bronchiectasis were randomised to receive ciprofloxacin powder, engineered to deposit in large and small airways, or placebo. Participants in the active group had a significant reduction in bacterial load, and 35% achieved eradication of Pseudomonas spp. The effects on exacerbations, C-reactive protein level, quality of life and lung function were not significant. Ciprofloxacin was well tolerated; however, increased resistance was observed. Bottom line: ciprofloxacin dry powder achieved a reduction in bacterial load. Summary: Patients aged ≥6 years with stable CF and chronic Pseudomonas aeruginosa lung infection (n=380) were randomised to an inhaled dry powder product containing colistimethate sodium 1662,500IU per capsule (Colobreathe) twice daily or three 28-day cycles of inhaled tobramycin 300 mg/5mL twice daily for 24 weeks in this open-label study. No significant difference was seen between the colistimethate versus tobramycin arms for change in percent predicted FEV 1 at week 24, with adjusted mean differences of -0.98% (95% CI -2.74, 0.86) and -0.56% (-2.71, 1.70) in the intent-to-treat (n=373) and perprotocol (n=261) analyses, respectively. Colistin-resistant isolate rates were ≤1.1% in both groups, and adverse events were similar.
Comment: This German study of 320 patients with CF investigated the role of a micronised dry powder inhalation of colistimethate. Nebulised colistimethate is effective in treatment of pseudomonal infection; however, nebulisation is rather cumbersome. The patients found the new inhaler easy to handle, and the colistimethate inhaler was as effective as tobramycin in reducing Pseudomonas burden. Only 1% colistimethate resistance was reported. At this stage, the NICE guidelines suggest the equal performance to inhaled tobramycin does not justify the higher expense. 
Patients with CF were randomised to receive 1 year of high-frequency chest wall oscillation (n=56) or PEP mask therapy (n=51) in this trial; 19 participants dropped out. Compared with PEP, high-frequency chest wall oscillation was associated with significantly more PEs (2.0 vs. 1.14) and shorter time to first PE (115 vs. 220 days; p=0.02), but no significant between-group difference was seen for lung function, health-related quality of life scores or patient satisfaction scores. Furthermore, PEP mask therapy was associated with a shorter treatment time.
Comment: Airway clearance is central in the management of CF. Methods include active cycle of breathing, PEP, oscillating PEP, autogenic and postural drainage, percussion and high-frequency chest wall oscillation. These Canadian physiotherapists reported a randomised trial comparing the efficacy of PEP treatment with high-frequency chest wall oscillation. The group using PEP treatment had fewer exacerbations and a longer time to the first exacerbation. Eleanor Main reflects on this well-conducted trial in her editorial (Thorax 2013; 68[8] :701-2), and also wonders if one should measure lung clearance index instead of FEV 1 . Bottom line: PEP masks are more effective than high-frequency chest wall oscillation for airway clearance in CF.
